Return to Special Authority drug list
PharmaCare is changing coverage of denosumab for osteoporosis. To maintain PharmaCare coverage, patients currently covered for the originator demosumab biologic product, Prolia®, must, in consultation with their prescriber, switch to the approved biosimilar product, Jubbonti®.
Prescribers may request a list of their patients prescribed Prolia brand of denosumab, so they can contact them to start the switch to Jubbonti®.
August 29, 2024
All new Special Authority (SA) requests, including renewals, for denosumab will only be approved for Jubbonti.
August 29, 2024 to March 3, 2025
During the six-month transition period, patients with PharmaCare coverage for the originator denosumab (Prolia) who wish to maintain their coverage must transition to the biosimilar denosumab (Jubbonti). A new SA request is not required until the next scheduled renewal date (if applicable). To maintain patients' coverage, prescribers must write a new prescription for their patients on the originator denosumab (Prolia), indicating the transition to biosimilar denosumab (Jubbonti).
March 4, 2025
The originator denosumab (Prolia) is no longer an eligible PharmaCare benefit and only biosimilar denosumab (Jubbonti) is authorized for continued coverage.
SA requests for patients who are unable to transition to biosimilar denosumab will be considered on an exceptional case-by-case basis.
Generic name: denosumab |
|
Strength & form |
60 mg/ mL pre-filled syringe |
Special Authority criteria |
Approval period |
For the treatment of women with postmenopausal osteoporosis or men with osteoporosis AND With clinical or radiographically documented fracture due to osteoporosis AND For whom oral bisphosphonates are contraindicated for one of the following reasons:
|
Indefinite |
For primary prevention of osteoporotic fractures in women with breast cancer who are receiving aromatase inhibitor therapy |
5 years |